Utang jangka cendhak marang ekuitas Notable Labs Ltd (NTBL)

Notable Labs, Ltd. (NTBL) management is implementing personalized therapy regimens to combat severe tumors. This price action on GURU.Markets is currently fixed at 0.00, which is attributed to a lack of stable cash flows due to the early stage of IT service development. High R&D expenditures and stringent FDA oversight, combined with protection via the PPMP system, create significant barriers to entry.

For Notable Labs, Ltd. (NTBL), which develops AI-driven live-cell screening in the B2B oncology diagnostics sector, the short-term debt-to-equity ratio reflects the dependence of operational stability on borrowed funds with maturities exceeding one year. This metric measures the proportion of long-term liabilities within the capital structure, where an increasing ratio signals heightened financial leverage and potential liquidity risks for the investor.